Wolfe Research moved Boston Scientific to a Peer Perform rating on Friday, concluding what it called the end of a multiyear bullish thesis for the medical device maker after two of the company’s principal growth engines weakened substantially in the first half of 2026.
The firm’s analyst, Mike Polark - who had been one of the stock’s advocates for four years - framed the change bluntly: "the call as we pitched it for 4 years has died." Polark adjusted his forecasts to reflect a significantly less robust trajectory for Boston Scientific, projecting roughly 7% organic revenue growth in 2027, earnings of $3.65 per share for that year, and a valuation that corresponds to a share price in the low $50s.
Two specific product lines underpinned the downgrade. On pulsed field ablation (PFA), Polark pointed to escalating competition from Abbott, which he said is driving a price and bundling battle ahead of Boston Scientific’s next meaningful catalysts - events that Wolfe does not expect until mid-2027 to 2028. The analyst described the competitive environment around PFA as intensifying and likely to pressure adoption or pricing near term.
For the Watchman left atrial appendage closure device, Wolfe highlighted a combination of developments that have raised concern about future volumes. Those include a series of clinical trial readouts, a reduction in the Watchman implanter fee, and capacity constraints in catheterization and electrophysiology labs - factors that together increase the prospect of outright declines in procedure volumes for the device.
Polark also reflected on the broader revenue mix that supported his prior bullish stance. He recalled a straightforward model the team often used: roughly 80% of revenue growing at 5%-7% and the remaining 20% - primarily PFA and Watchman - growing at 20%-30%, producing overall organic growth near 10%. "And now? It’s like…100% of revenue grows 5%-7%," he wrote, underscoring the loss of the high-growth components.
Capital allocation choices contributed to Wolfe’s reassessment. Polark characterized the Axonics acquisition as a "disaster" and raised concerns about execution risk across recent transactions, citing the company’s deal track record as an additional factor in the rating change.
Context and implications
The downgrade reflects a near-term recalibration of expectations for Boston Scientific’s growth profile, driven by competitive and operational dynamics specific to two products that had previously been viewed as accelerants. The analyst’s revised model offers a more modest organic growth path and lower near-term earnings, while identifying timing for next potential catalysts in the mid-2027 to 2028 window.